Progyny, Inc. Announces Pricing of Initial Public Offering
25 October 2019 - 11:01AM
Progyny, Inc., a leading benefits management company specializing
in fertility and family building benefits solutions in the United
States, today announced the pricing of its initial public offering
of 10,000,000 shares of its common stock at a price to the public
of $13.00 per share. Progyny is offering 6,700,000 shares and the
selling stockholders are offering 3,300,000 shares. In addition,
certain selling stockholders have granted the underwriters a 30-day
option to purchase up to an additional 1,500,000 shares of common
stock at the initial public offering price less the underwriting
discount. The shares are expected to begin trading on the Nasdaq
Global Select Market under the ticker symbol “PGNY” on October 25,
2019, and the offering is expected to close on October 29, 2019,
subject to customary closing conditions.
J.P. Morgan, Goldman Sachs & Co. LLC and
BofA Securities are acting as joint lead book-running managers for
the offering. Citigroup is acting as book-running manager for the
offering. Piper Jaffray, SVB Leerink and TPG Capital BD, LLC are
acting as co-managers for the offering.
The offering is being made only by means of a
prospectus. Copies of the final prospectus, when available, may be
obtained from: J.P. Morgan Securities LLC, 383 Madison Avenue, New
York, New York 10179, Attn: Prospectus Department, Telephone:
866-803-9204, Email: prospectus-eq_fi@jpmchase.com; Goldman Sachs
& Co. LLC, 200 West Street, New York, New York 10282, Attn:
Prospectus Department, Telephone: 866-471-2526, Facsimile:
212-902-9316, Email: prospectus-ny@ny.email.gs.com; and BofA
Securities, One Bryant Park, New York, New York 10036, Attn:
Prospectus Department, Email: dg.prospectus_requests@baml.com.
A registration statement relating to these
securities has been filed with, and declared effective by, the U.S.
Securities and Exchange Commission (SEC). Copies of the
registration statement can be accessed through the SEC’s website at
www.sec.gov. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Progyny
Progyny is a leading fertility benefits
management company in the United States. We are redefining
fertility and family building benefits, proving that a
comprehensive and inclusive fertility solution can simultaneously
benefit employers, patients, and physicians. Our benefits solution
empowers patients with education and guidance from a dedicated
Patient Care Advocate (PCA), provides access to a premier network
of fertility specialists using the latest science and technologies,
reduces healthcare costs for the nation’s leading employers, and
drives optimal clinical outcomes. We envision a world where anyone
who wants to have a child can do so.
Contact
Progyny PR
Selena Yang
media@progyny.com
Progyny IR
James Hart
investors@progyny.com
Progyny (NASDAQ:PGNY)
Historical Stock Chart
From Apr 2024 to May 2024
Progyny (NASDAQ:PGNY)
Historical Stock Chart
From May 2023 to May 2024